NEW YORK (GenomeWeb News) – Varian today said that its shareholders have approved the firm's merger agreement with Agilent Technologies.

The deal, under which Agilent will acquire Varian for $52 per share in cash — for a total transaction value of around $1.5 billion — was announced in late July.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.